Xynomic制药从勃林格殷格翰获得mTORC1 / 2抑制剂的全球**经营权

2018-12-22 MedSci MedSci原创

Xynomic制药是一家临床阶段的肿瘤药物开发公司,近日宣布,它已从勃林格殷格翰获得开发、生产和商业化BI 860585的全球独家许可,BI 860585是一款即用型mTORC1 / 2抑制剂。

Xynomic制药是一家临床阶段的肿瘤药物开发公司,近日宣布,它已从勃林格殷格翰获得开发、生产和商业化BI 860585的全球独家许可,BI 860585是一款即用型mTORC1 / 2抑制剂。

BI 860585是一种有效且具有选择性的ATP竞争性mTOR丝氨酸/苏氨酸激酶抑制剂。它已经在I期试验中进行了测试,其中90名患有晚期实体肿瘤的患者将其作为单一药物,或与依西美坦及紫杉醇联合使用。在该试验中,BI 860585耐受性良好,疾病控制率高达58%。Xynomic计划在未来6-9个月内启动2临床试验,其中一项是将BI 860585乳腺癌标准治疗相结合的关键性II期试验,另一项是将BI 860585XynomicXP-102结合治疗直肠癌。根据世界卫生组织(WHO)国际癌症研究机构于2018912日发布的新闻稿,乳腺癌是最常诊断的癌症,也是女性癌症死亡的主要原因。此外,结肠直肠癌是第二常见的癌症,是女性癌症死亡的第三大原因,也是男性中第三大常见癌症。根据IMSiHealthcareanalyst的分析,治疗这两种恶性肿瘤的药物预计到2023年将产生约254亿美元的市场。


原始出处:

http://www.firstwordpharma.com/node/1612999#axzz5aJrWexZu

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1995546, encodeId=8b2619955466d, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Mon May 20 07:50:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851869, encodeId=14c71851869c0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 26 19:50:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418398, encodeId=64c31418398c6, content=<a href='/topic/show?id=2cc91232947' target=_blank style='color:#2F92EE;'>#mTORC1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12329, encryptionId=2cc91232947, topicName=mTORC1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59413348493, createdName=雕雕, createdTime=Mon Dec 24 07:50:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447255, encodeId=df2e144e25515, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Mon Dec 24 07:50:00 CST 2018, time=2018-12-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1995546, encodeId=8b2619955466d, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Mon May 20 07:50:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851869, encodeId=14c71851869c0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 26 19:50:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418398, encodeId=64c31418398c6, content=<a href='/topic/show?id=2cc91232947' target=_blank style='color:#2F92EE;'>#mTORC1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12329, encryptionId=2cc91232947, topicName=mTORC1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59413348493, createdName=雕雕, createdTime=Mon Dec 24 07:50:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447255, encodeId=df2e144e25515, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Mon Dec 24 07:50:00 CST 2018, time=2018-12-24, status=1, ipAttribution=)]
    2019-08-26 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1995546, encodeId=8b2619955466d, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Mon May 20 07:50:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851869, encodeId=14c71851869c0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 26 19:50:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418398, encodeId=64c31418398c6, content=<a href='/topic/show?id=2cc91232947' target=_blank style='color:#2F92EE;'>#mTORC1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12329, encryptionId=2cc91232947, topicName=mTORC1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59413348493, createdName=雕雕, createdTime=Mon Dec 24 07:50:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447255, encodeId=df2e144e25515, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Mon Dec 24 07:50:00 CST 2018, time=2018-12-24, status=1, ipAttribution=)]
    2018-12-24 雕雕
  4. [GetPortalCommentsPageByObjectIdResponse(id=1995546, encodeId=8b2619955466d, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Mon May 20 07:50:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851869, encodeId=14c71851869c0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 26 19:50:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418398, encodeId=64c31418398c6, content=<a href='/topic/show?id=2cc91232947' target=_blank style='color:#2F92EE;'>#mTORC1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12329, encryptionId=2cc91232947, topicName=mTORC1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59413348493, createdName=雕雕, createdTime=Mon Dec 24 07:50:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447255, encodeId=df2e144e25515, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Mon Dec 24 07:50:00 CST 2018, time=2018-12-24, status=1, ipAttribution=)]

相关资讯

Nature:Treg细胞与代谢适应性有关

表达Foxp3的“调控性T细胞”(Treg) 在免疫耐受和动态平衡中起中心作用。在这项研究中,Hongbo Chi及其同事发现,mTORC1依赖型胆固醇生物合成对于Treg功能很重要,部分通过增加Treg“效应子”分子CTLA4 和ICOS发挥作用。这一发现说明,在免疫信号与细胞的代谢状态之间存在一个联系。 Zeng H, Yang K, Cloer C, Neale G, Vogel P,

Cell:饿死癌细胞?恐怕没那么简单

本文亮点: Ras介导的对胞外蛋白的巨胞饮过程是细胞内必需氨基酸的重要来源。 溶酶体对胞外蛋白进行降解会激活mTORC1信号途径 mTORC1能够抑制溶酶体对胞外蛋白的异化作用 抑制mTORC1可以促进处于氨基酸饥饿状态的细胞以及血管较少的肿瘤的生长 近日,来自美国的科学家在著名国际学术期刊Cell在线发表了一项最新研究进展,他们发现细胞利用溶酶体对胞外蛋白进行降解获得氨基酸会受到

CLIN CANCER RES:利用放射性标记转铁蛋白无创检测mTORC1信号

mTOR调节许多正常的生理过程,当其活性过高时可以导致多种肿瘤及疾病的发生。在动物模型及人体中无创检测mTOR信号难度很大。CLIN CANCER RES近期发表了一篇文章,研究利用核显像工具检测细胞内mTOR活性。

PNAS:SAD-A激酶通过mTORC1信号调控胰岛β细胞形态和功能

日前,来自南京医科大学,美国宾州大学医学院等机构的研究人员在最新研究中发现了一种激酶: SAD-A 能作为 mTOR 复合物1( mTORC1 )信号的传递因子,调控胰岛 β 细胞的形态和功能,由此揭示了一种 mTORC1 信号调控的新机制。【原文下载】 上述研究论文刊登在了近期出版的PNAS杂志上,文章的通讯作者分别是南京医科大学基础医学院韩晓教授,以及美国宾州大学史裕光教授,这两位学者均

Nature:从结构上揭示出mTORC1的作用机制

作为一种主控生长调节因子,细胞中的一种被称作mTORC1的蛋白复合物检测细胞何时具有足够的用于生长和分裂的营养物。

Cell:溶酶体释放必需氨基酸以及蛋白质作为营养物质时激活mTORC1的SLC38A9是必要的。

mTORC1激酶通过对环境因素,包括氨基酸的感应对细胞的生长调节有十分重要的意义。通过精氨酸激活mTORC1需要SLC38A9,这是一种与氨基酸转运蛋白具有同源性的溶酶体膜蛋白,目前对SLC38A9的研究甚少,对其机制和作用的理解十分有限。